Alcohol Dependence: Pharmacotherapy, Pharmacogenetics, and Genetics
酒精依赖:药物治疗、药物遗传学和遗传学
基本信息
- 批准号:7789394
- 负责人:
- 金额:$ 18.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-02-01 至 2011-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAlcohol dependenceAlcoholismAlcoholsAnticonvulsantsApplications GrantsArtsAwardClinicalClinical ResearchClinical TrialsCollaborationsCommunicationComplementControlled Clinical TrialsDataDevelopmentEthicsFundingGeneticGenomicsGoalsHealthHeavy DrinkingHumanHuman GeneticsInterventionKnowledgeLeadershipLearningManuscriptsMedicalMentored Patient-Oriented Research Career Development AwardMentorsMentorshipMethodsNaltrexonePatientsPharmacogeneticsPharmacotherapyPilot ProjectsPlacebo ControlPlacebosPopulationPreparationPublic HealthRandomizedResearchResearch PersonnelResearch ProposalsScientistSertralineStagingStatistical MethodsSupervisionTrainingTranslatingTreatment outcomeUnited StatesWorkalcohol abuse therapyalcohol researchalcohol responsealcohol use disorderalcoholism therapycareercareer developmentdesigndrinkingeffective therapyexperienceimprovednovelpatient oriented researchprogramspublic health relevanceskill acquisitionskillsstatisticstopiramatetreatment trial
项目摘要
DESCRIPTION (provided by applicant): In view of the growing demand for new and more effective treatments for alcohol use disorders (AUDs), which are highly prevalent in the population, a need exists for investigators with expertise in the conduct of alcohol treatment research.. There is also a need for researchers who are conversant with human genetics and in particular, pharmacogenetics, to translate these rapidly evolving fields into meaningful advances in the treatment of patients with AUDs. I propose a four-year plan of mentored patient-oriented research (POR) at the the NIAAA-funded Alcohol Research Center at the Univ. of CT Health Center under the supervision and mentorship of Dr. Henry Kranzler. The plan includes completion of substantial coursework and mentoring in applied statistics, with an emphasis on the application of pharmacogenetics to both the acute response to alcohol and the treatment of alcohol dependence. I will also complete coursework in translational genomics to assist me in achieving my main goal of developing an independent program of research on the application of pharmacogenetics to clinical trials for alcohol dependence by the end of the four-year career award period. I will complete a 12-week randomized, placebo-controlled clinical trial of the novel anticonvulsant zonisamide in 40 alcohol dependent subjects, which will provide me with pilot data for additional research proposals. I will also continue my work in ongoing trials and human alcohol challenge studies, all of which include pharmacogenetic components. The acquisition of new skills will be achieved through formal coursework (including the ethical conduct of research) and continued collaboration with established investigators and the ongoing receipt of mentoring in clinical trials and pharmacogenetics (to enable me to apply the skills learned in the classroom in the context of ongoing clinical research). I will also continue to develop my skills in grantsmanship, manuscript preparation, effective communication, academic collaboration, and leadership. This revised application contains substantial revisions resulting in well-focused career development and research plans, and explication of the need for further training. Receipt of this award is key to my continued development as a clinical alcohol researcher.
PUBLIC HEALTH RELEVANCE: This research will focus on improving medical treatments for alcoholism, a condition that continues to be prevalent in the United States, and is a major public health concern. This research will provide for the training and development of a medical scientist who will specialize in developing state of the art medical interventions to improve treatment and outcomes for patients with alcoholism.
描述(由申请人提供):鉴于对酒精使用障碍(AUDs)的新的和更有效的治疗方法的需求不断增长,这在人群中非常普遍,需要具有进行酒精治疗研究的专业知识的研究人员。还需要熟悉人类遗传学,特别是药物遗传学的研究人员,将这些快速发展的领域转化为治疗AUDs患者的有意义的进展。我建议在niaa资助的CT大学健康中心酒精研究中心,在Henry Kranzler博士的监督和指导下,开展一项为期四年的指导病人导向研究(POR)计划。该计划包括完成应用统计学方面的大量课程和指导,重点是将药物遗传学应用于酒精急性反应和酒精依赖治疗。我还将完成翻译基因组学的课程,以帮助我实现我的主要目标,即在四年的职业奖励期结束时,开发一个独立的药物遗传学应用于酒精依赖临床试验的研究项目。我将在40名酒精依赖者中完成一项为期12周的新型抗惊厥药唑尼沙胺的随机、安慰剂对照临床试验,这将为我进一步的研究提案提供先导数据。我还将继续在正在进行的试验和人类酒精挑战研究中工作,所有这些都包括药物遗传成分。新技能的获得将通过正式的课程学习(包括研究的道德行为),与已建立的研究人员的持续合作,以及在临床试验和药物遗传学方面的持续指导(使我能够将课堂上学到的技能应用于正在进行的临床研究)来实现。我还将继续提高我在资助、稿件准备、有效沟通、学术合作和领导方面的技能。这一修订后的申请包含了大量的修订,从而产生了重点突出的职业发展和研究计划,并说明了进一步培训的需要。获得这个奖项对我作为临床酒精研究人员的继续发展至关重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALBERT JOSEPH ARIAS其他文献
ALBERT JOSEPH ARIAS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALBERT JOSEPH ARIAS', 18)}}的其他基金
Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
透皮罗替高汀作为可卡因使用障碍行为疗法的辅助疗法
- 批准号:
10615366 - 财政年份:2022
- 资助金额:
$ 18.35万 - 项目类别:
Olanzapine Augmentation in OUD Patients on Buprenorphine-Naloxone with Comorbid Symptoms of Serious Mental Illness (SMI): A Prospective Observational 8-week Pilot Study
患有严重精神疾病 (SMI) 共病症状的 OUD 患者服用丁丙诺啡-纳洛酮时奥氮平强化治疗:一项为期 8 周的前瞻性观察性试点研究
- 批准号:
10395719 - 财政年份:2021
- 资助金额:
$ 18.35万 - 项目类别:
Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders
物质使用障碍药物治疗早期临床评价实验室
- 批准号:
10553087 - 财政年份:2020
- 资助金额:
$ 18.35万 - 项目类别:
Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders
物质使用障碍药物治疗早期临床评价实验室
- 批准号:
9894325 - 财政年份:2020
- 资助金额:
$ 18.35万 - 项目类别:
Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders
物质使用障碍药物治疗早期临床评价实验室
- 批准号:
10348209 - 财政年份:2020
- 资助金额:
$ 18.35万 - 项目类别:
Zonisamide Treatment of Alcohol Use Disorder: An Evaluation of Efficacy and Mechanism of Action
唑尼沙胺治疗酒精使用障碍:疗效和作用机制评价
- 批准号:
9629630 - 财政年份:2019
- 资助金额:
$ 18.35万 - 项目类别:
Effectiveness of Zonisamide in the Treatment of Alcohol Dependent Veterans
唑尼沙胺治疗酒精依赖退伍军人的有效性
- 批准号:
8819717 - 财政年份:2015
- 资助金额:
$ 18.35万 - 项目类别:
Alcohol Dependence: Pharmacotherapy, Pharmacogenetics, and Genetics
酒精依赖:药物治疗、药物遗传学和遗传学
- 批准号:
8019616 - 财政年份:2010
- 资助金额:
$ 18.35万 - 项目类别:
Alcohol Dependence: Pharmacotherapy, Pharmacogenetics, and Genetics
酒精依赖:药物治疗、药物遗传学和遗传学
- 批准号:
8423079 - 财政年份:2010
- 资助金额:
$ 18.35万 - 项目类别:
相似海外基金
Role of glucocorticoid receptor-mediated mRNA decay in alcohol dependence
糖皮质激素受体介导的 mRNA 衰减在酒精依赖中的作用
- 批准号:
10811212 - 财政年份:2023
- 资助金额:
$ 18.35万 - 项目类别:
6/11 Astrocyte-specific changes and interventions in alcohol dependence
6/11 星形胶质细胞特异性变化和酒精依赖干预
- 批准号:
10591606 - 财政年份:2022
- 资助金额:
$ 18.35万 - 项目类别:
An Investigation of Reward Processing in Co-occurring Alcohol Dependence and Loss of Control Eating
对同时发生的酒精依赖和饮食失控的奖励处理的研究
- 批准号:
486597 - 财政年份:2022
- 资助金额:
$ 18.35万 - 项目类别:
Studentship Programs
Identifying new targets for the treatment of alcohol dependence and relapse: epigenetic analysis of the abstinent brain
确定治疗酒精依赖和复发的新靶点:戒酒大脑的表观遗传学分析
- 批准号:
10396660 - 财政年份:2022
- 资助金额:
$ 18.35万 - 项目类别:
Identifying new targets for the treatment of alcohol dependence and relapse: epigenetic analysis of the abstinent brain
确定治疗酒精依赖和复发的新靶点:戒酒大脑的表观遗传学分析
- 批准号:
10553449 - 财政年份:2022
- 资助金额:
$ 18.35万 - 项目类别:
6/11 Astrocyte-specific changes and interventions in alcohol dependence
6/11 星形胶质细胞特异性变化和酒精依赖干预
- 批准号:
10409263 - 财政年份:2022
- 资助金额:
$ 18.35万 - 项目类别:
Novel GLT-1 activators for the treatment of alcohol dependence: preclinical studies
用于治疗酒精依赖的新型 GLT-1 激活剂:临床前研究
- 批准号:
10517529 - 财政年份:2022
- 资助金额:
$ 18.35万 - 项目类别:
Reducing alcohol-seeking behavior in a rat model of alcohol dependence
减少酒精依赖大鼠模型的寻酒行为
- 批准号:
10684236 - 财政年份:2022
- 资助金额:
$ 18.35万 - 项目类别:
Opposing Contributions of Oxytocin and Corticotropin-Release Factor to Alcohol Dependence
催产素和促肾上腺皮质激素释放因子对酒精依赖的相反作用
- 批准号:
10451814 - 财政年份:2021
- 资助金额:
$ 18.35万 - 项目类别:
Opposing Contributions of Oxytocin and Corticotropin-Release Factor to Alcohol Dependence
催产素和促肾上腺皮质激素释放因子对酒精依赖的相反作用
- 批准号:
10655413 - 财政年份:2021
- 资助金额:
$ 18.35万 - 项目类别: